ChromaTwist lands second round of equity funding to develop fluorescent dyes for the flow cytometry market
University of Birmingham spinoutChromaTwist Ltd has secured £487k of equity investment to develop its new class of fluorescent dyes for the flow cytometry reagent market.
Symbolic image
Computer-generated image
This second round of equity investment, which brought in funds from Directors, existing Angel investors, angelgroups and the University of Birmingham will allow the company to continue product development with industry partners, and enable rapid development of products for market entry as soon as 2023.
Flow cytometry is an analytical technique used by hospital laboratories, the pharmaceutical industry, and university research departments, for medical research, vaccine and drug development and disease diagnosis. It uses dyes to detect or measure the characteristics of cells or particles.
The market for these reagents is showing significant growth, with an estimated value of $2.9Bn by 2027.
One of the central challenges in flow cytometry is the ability to detect multiple targets from the same sample (known as ‘multiplexing’). The novel dyes in development by ChromaTwist show exceptional versatility with a large range of ‘signalling colours’, and this should enable simultaneous tests to be carried out on a single sample, which increases throughput and speeds output from existing flow cytometry equipment.
The dyes were discovered by the research groups led by Professor Jon Preece from the School of Chemistry and Professor Alex Robinson from the School of Chemical Engineering, during a programme of research into photo-conducting liquid crystals. The group, which has world-leading expertise in nanoscale materials, quickly realised they had found materials with a unique chemistry that allows tuneable fluorescence, meaning that small adjustments in the molecular structure alter the colour of the light they emit, from blue through to red, and potentially into the infra-red. The technology is protected by a suite of patents owned by ChromaTwist.
The funding builds on initial grant funding of £347k from Innovate UK, £90k funding from the Directors in 2019, and a first equity funding round of £430k from directors, Angel investors and the University of Birmingham in 2021.
Since then, ChromaTwist has made significant progress, developing a proof-of-concept product and initiating testing with major players in the flow cytometry reagent market.
Professor Jon Preece commented: “Following a year of rapid product development and customer engagement, we have now moved to our own dedicated laboratory and will be expanding our team of scientists, so we can expedite our dye development for flow cytometry. We expect the resulting dyes to be fully compatible with existing flow cytometry processes and equipment, and are looking forward to the next 12 months working with industry partners.”
The founders Preece and Robinson are serial innovators, who have already worked together on an existing spinout, Irresistible Materials Ltd, which develops organic materials for new lithographic processes including e-beam and EUV lithography. ChromaTwist has an experienced management team including Chairman, Mark Shepherd (and CEO Irresistible Materials Ltd), who has extensive experience in licensing and spin out companies, and Darren Wake, who has three decades of executive level experience including M&A.
ChromaTwist has already received commercial accolades and was nominated as ‘one to watch’ in The Spinoff Prize 2020, which is organised by Nature Research, part of Springer Nature, and German leading science and technology company Merck KGaA, as well as being Royal Society of Chemistry Emerging Technologies finalists in 2019.
ChromaTwist is also evaluating longer-term opportunities in other sectors, including security inks and applications in organic electronics, having demonstrated the materials can be incorporated into OPVs and OLED devices as the active element. To this end, ChromaTwist has sold 18 of its dyes to Sigma-Aldrich, part of the Life Science business sector of Merck, and is open to initial discussion with companies about potential partnerships and collaborations in these areas.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
